Pace Logo

News Category: Life Sciences

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried …

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract Read More »

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it …

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts

Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences, a division of Pace® Science and Technology Company, is pleased to announce that it has received a Bronze Award for its current state of sustainability. This award signifies that Pace® is in the top 50% …

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts Read More »

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf

Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar presented by Dave Barnes, Ph.D., Vice President of Scientific Affairs for Pace® Life Sciences. To watch it live, tune in on Thursday, April 14 at 11 AM EDT. REGISTER HERE REGISTER HERE This presentation focuses …

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf Read More »

The Changing Landscape of Gene Therapy

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The Changing Landscape of Gene Therapy, written by Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace® Life Sciences (PLS). Read the full article

Pace® Life Sciences Acquires Velesco Pharmaceutical Services

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development …

Pace® Life Sciences Acquires Velesco Pharmaceutical Services Read More »

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity and Injectable Drug Product Services

Acquisition allows Pace to support a growing number of clients requiring services throughout the drug development process while adding expertise on drug-device combination products and extended-release injectable technologies. Minneapolis, MN, July 23, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development and manufacturing organization (CDMO), today …

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity and Injectable Drug Product Services Read More »

PRESS RELEASE: June 2021: Installation and validation of LIMS is complete in our Philadelphia site!

The installation and validation of our LabVantage Laboratory Information Management System (LIMS) is complete in our Philadelphia site!   Staff at our Philadelphia site worked together with cross-functional teams in Quality, Operations, IT, CSols, Inc. and LabVantage (vendor) to complete the installation and validation of a highly-functional and GMP compliant LIMS system. Lou Forcellini, site …

PRESS RELEASE: June 2021: Installation and validation of LIMS is complete in our Philadelphia site! Read More »

Delivering Science Better; Advancing Novel Therapies Through the Clinic to Commercialization

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Drug Development and Delivery recently interviewed our very own, Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace Analytical® Life Sciences (PLS). After two recent acquisitions, Pace now operates five state-of-the-art facilities, and is well-equipped to handle almost any project regardless of scope or …

Delivering Science Better; Advancing Novel Therapies Through the Clinic to Commercialization Read More »